Literature DB >> 7448754

Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice.

J A Houghton, S J Maroda, J O Phillips, P J Houghton.   

Abstract

The level of thymidylate synthetase (EC 2.1.1.45) and its activity have been measured in a series of human colorectal adenocarcinomas growing as xenografts in immune-deprived mice. Enzyme activity varied between 8.4 and 124 pmol per mg protein per hr; within each tumor line, this activity correlated with the capacity to bind [6-3H]5-fluoro-2'-deoxyuridine 5'-monophosphate ([6-3H]FdUMP), which varied between 0.16 and 1.68 pmol [6-3H]FdUMP bound per g tissue. Highest and lowest activities were measured in tumor lines that were insensitive to 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine. The ratio of the maximum free FdUMP concentration to thymidine 5'-monophosphate synthetase-binding activity did not differentiate fluorinated pyrimidine-responsive lines from those innately insensitive. Maximum potential binding of [6-3H]FdUMP in vitro was measured without addition of dl-L-5,10-methylenetetrahydrofolate (CH2FH4) in cytosol from two tumor lines, both of which demonstrated some sensitivity to fluorinated pyrimidine therapy. The other four insensitive tumor lines required CH2FH4 to be added in order to attain maximum [6-3H]FdUMP binding. Similar data were obtained using nitrocellulose membrane filtration to isolate both covalent and noncovalent complexes. Direct measurement of thymidine 5'-monophosphate synthetase activity after incubation of tumor cytosols with FdUMP, with or without added CH2FH4 showed that, in nonresponsive tumors, maximum enzyme inhibition was achieved only in the presence of exogenous cofactor. It is suggested that the availability of cofactor may prove important in the formation of the ternary complex CH2FH4:thymidine 5'-monophosphate synthetase:FdUMP when high concentrations of FdUMP are present for only short periods of time.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7448754

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.

Authors:  H Bailey; G Wilding; K D Tutsch; R Z Arzoomanian; D Alberti; M B Tombes; J L Grem; D R Spriggs
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.

Authors:  P Ragnhammar; H Blomgren
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

3.  Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase.

Authors:  Hiroaki Tsujimoto; Sayaka Tsukioka; Satoru Ono; Etsuko Sakamoto; Kazuki Sakamoto; Kohji Tsuta; Fumio Nakagawa; Hitoshi Saito; Junji Uchida; Mamoru Kiniwa; Masakazu Fukushima
Journal:  Oncol Lett       Date:  2010-09-17       Impact factor: 2.967

4.  Mutants of human colon adenocarcinoma, selected for thymidylate synthase deficiency.

Authors:  P J Houghton; G S Germain; B J Hazelton; J W Pennington; J A Houghton
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

5.  Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid.

Authors:  J L Abbruzzese; R Amato; S Schmidt; M N Raber; P Frost
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 6.  Predictive tests in cancer chemotherapy. A reappraisal.

Authors:  R Osieka; S Seeber; C G Schmidt
Journal:  Klin Wochenschr       Date:  1984-03-01

Review 7.  Biochemical mechanisms in colon xenografts: thymidylate synthase as a target for therapy.

Authors:  P J Houghton; J A Houghton; B J Hazelton; S Radparvar
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

8.  A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.

Authors:  Robert P Whitehead; Jacqueline K Benedetti; James L Abbruzzese; Bach Ardalan; Stephen Williamson; Ellen R Gaynor; Stanley P Balcerzak; John S Macdonald
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

9.  Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.

Authors:  C Erlichman; B Mitrovski
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Effect of concurrent calcium leucovorin infusion on 5-fluorouracil cytotoxicity against murine L1210 leukemia.

Authors:  P Klubes; I Cerna; M A Meldon
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.